New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
10:58 EDTCRIS, OXBTCuris, Oxygen Bio advance after FDA lifts clinical holds on treatments
Shares of both Curis (CRIS) and Oxygen Biotherapeutics (OXBT) are higher this morning after the Food and Drug Administration lifted clinical holds on treatments being tested by the companies. Curis is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies; Oxygen Biotherapeutics is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. CURIS: Curis said the FDA allowed it to resume testing of CUDC-427, its experimental cancer drug, lifting a November 2013 order halting enrollment in an early-stage trial. The trial was put on partial clinical hold in November following the death of a patient who progressed to liver failure approximately one month following the discontinuation of CUDC-427 dosing. The company says the monotherapy Phase 1 study will re-open "as soon as possible." Curis President and COO Ali Fattaey said the company believes CUDC-427 has "significant potential" as an anti-cancer agent and that the company expects to proceed with CUDC-427's overall development plan, "including our planned study to investigate CUDC-427 in combination with capecitabine in HER-2 negative advanced breast cancer patients." OXYGEN: Separately, Oxygen Biotherapeutics this morning said it received written confirmation from the FDA that the clinical hold on its Oxycyte development program was lifted following its review of the September 12, 2013, submission to the investigational new drug application for Perfluorocarbon Oxycyte. The FDA said the company has addressed all clinical hold issues. PRICE ACTION: Curis is trading up 7c, or 2.55%, to $2.82 in morning trading. Meanwhile, Oxygen Biotherapeutics is up 25c, or 4.65%, to $5.63.
News For CRIS;OXBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
07:21 EDTCRISCuris announces allowance of U.S. patent
Curis announced the receipt of a Notice of Allowance of a U.S. patent that covers a broad genus of compounds that target histone deacetylase, or HDAC, and phosphoinositide 3-kinase, or PI3K, activities in a single chemical structure including CUDC-907, Curis' oral, dual HDAC and PI3K small molecule inhibitor that is currently being studied in Phase 1 clinical trials. This patent, along with prior patents issued to Curis, further strengthens the Company's intellectual property portfolio of compounds including CUDC-907 that inhibit HDAC and PI3K enzymes in a single small molecule for the treatment of certain human diseases. Collectively, these patents generically cover composition-of-matter and methods of use of CUDC-907 as well as a broad range of proprietary chemical entities that target HDAC and PI3K enzymes, and in some instances mammalian target of rapamycin, within a single molecule for the treatment of certain human diseases.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use